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China’s output in fundamental stem cell research has increased markedly in recent years. Vigorous public
investment and infrastructure development have enabled major productivity gains, but challenges in regula-
tion, governance, and the management of clinical expectations must be addressed to ensure scientific
quality and sustainable growth.China’s scientific renaissance in recent
years has been as dramatic as its
economic rise, allowing the world’s most
populous country to also become one of
the most prolific in terms of research
output. Significant government invest-
ments in education, infrastructure, and
funding—coupledwith increasingly strong
interactions between Chinese scientists
both at home and overseas—have re-
turned the nation to the front ranks of inter-
national scientific productivity. This is
clearly the case in the field of stem cell
research, which has been a focal point
of the government’s plan for developing
the life sciences and biomedical sectors.
In this Forum, we look at the public initia-
tives and research efforts that have led to
China’s emergence as a global stem cell
power, examine present-day challenges
and achievements, and look ahead to
future directions.
The roots of stem cell research in China
can be traced back nearly half a century to
1963, when embryologist Dizhou Tong
generated the world’s first cloned fish,
an Asian carp, by somatic cell nuclear
transfer (Tong et al., 1963). The following
year, hematologist Dao-Pei Lu at Peking
University People’s Hospital performed
China’s first syngeneic bone marrow
transplantation for the treatment of
severe aplastic anemia (Lu, 1981). The
work on mouse hematopoietic stem cell
kinetics in the late 1970s led by Chu-tse
Wu represented some of the earliest
efforts in stem cell biology in China (Wu
et al., 1985). These, together with many12 Cell Stem Cell 10, January 6, 2012 ª2012other achievements, stood for years as
an early promise of things to come.
Following 3 decades of economic restruc-
turing and growth since the late 1970s,
China is now increasingly able to address
its national goals in higher education,
research and development, and public
health. As with many Asian countries
looking to diversify their economies to
embrace a more innovation-based ap-
proach, China has looked to stem cell
research with great interest in recognition
of its rapid pace of advances and
tremendous clinical promise. The ensuing
concentration of funding and facilities
by national, provincial, and municipal
governments—and the absence of public
controversies that have hampered work in
areas such as human embryonic stem
cells (hESCs) in some countries in the
West—has enabled China to build a
stem cell research community nearly
from the ground up in a single decade.
Enormous strides have been made in the
quantity and quality of China’s research
output in fundamental, translational, and
clinical areas of the stem cell field, even
as comparedwith the situation as recently
as 5 years ago (Murray and Spar, 2006).
While these efforts remain very much
a work in progress, the rapid pace of
development and increased research
quality are promising signs of things to
come.
Self-Renewal
In 1986, China launched a major applied
research initiative known as the ‘‘863’’Elsevier Inc.plan, and a basic science research
program under its later counterpart, the
‘‘973’’ plan, both administered by the
Ministry of Science and Technology
(MOST) (http://program.most.gov.cn/). In
2001, two independent stem cell 973
programs (led by Lingsong Li and Huizhen
Sheng) were launched. Until recently,
most stem cell basic research projects
were funded under the Development and
Reproduction Key Program, a derivative
of the 973 plan. A number of subsequent
funding initiatives intended to further
promote stem cell research, applications,
and public awareness have been estab-
lished by MOST and other ministries
and public agencies, as summarized in
Table 1. Of these, the National Natural
Science Foundation of China (NSFC) in
particular has seen its budget increase
by over 20% per annum since 1986; its
2011 budget stands at 12.4 billion RMB
($1.95 billion), an increase of more than
50% from the previous year (of this
amount, 226 million RMB [$35.5 million]
is allocated to stem cell research). In total,
the national government’s stem cell
research funding commitment is esti-
mated at more than 3 billion RMB (close
to $500 million) over the next 5 years.
This amount excludes local government
funding, industry support, and other initia-
tives, such as the National New Drug
Development Plan.
Clearly, stem cell research is enjoying
significant investment by various funding
agencies and sectors in China, but the
country still needs to work out how to
Table 1. Stem Cell Research Funding Mechanisms in China
Agency Program Grant Sizea 2011 Funding Levelb
NSFC general programs 92.3 1,405
key program 452 224.4
major program 3,000 6–9
total stem cell funding varies 223
MOST 863 1,000–5,000 –
973 3,000–5,000 –
stem cell program 4,600 40
stem cell initiative for CAS 1,500 150
Other ministries, provinces, cities,
major universities, industry
varies; mainly follow NSFC and/or
MOST funding mechanisms
varies; usually smaller than similar
NSFC programs, except for a few
special initiatives
total annual funding estimated
to exceed the NSFC total
aUnit = Thousands, US dollars.
bUnit = Millions, US dollars.
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parent competition and effective use.
While some laboratories may have re-
ceived extraordinary funding for supplies
and equipment, under the current policies
most grants cannot be used for staff
salaries, and principal investigators do
not have the right to hire laboratory
members at competitive compensation
scales based on their actual funding
levels, or to do so to reflect long-term
goals. The lack of measures to link future
funding allocations to objective indicators
of scientific performance and impact is
also problematic. Appropriate gover-
nance measures, such as ensuring that
funding and hiring decisions are fair and
transparent and providing mechanisms
for monitoring research integrity and
outcomes, will be crucial to the success
of China’s stem cell commitments.
Rapid Proliferation
A look at international publication trends
shows how the country’s investments
are already beginning to pay a dividend
in scientific productivity. From 2006 to
2010, China’s stem cell research output
jumped from 176 articles to 677, a 285%
increase (see Table 2). This represents
an increase from less than 3% of the
world total of stem cell research publica-
tions to more than 7%. While this repre-
sents only about one-fifth of the US total
(US stem cell publications comprise
38% of the world total), China’s prolific
output has neared that of Japan, and
stands to outpace it in 2011 if current
trends continue.
Some of China’s stem cell work has
already gained international recognition.Following the first report of induced
pluripotent stem cells (iPSCs), Chinese
scientists were quick to adopt the tech-
nology and soon made contributions to
this rapidly developing field, such as iden-
tification of p53 as amajor barrier for iPSC
generation (Zhao et al., 2008), some of the
first evidence for the pluripotency of
mouse iPSCs (Kang et al., 2009; Zhao
et al., 2009), and the importance of
mesenchymal-epithelial transition (MET)
to iPSC induction (Li et al., 2010). A
number of iPSC lines have also been
derived from novel species, such as rat,
pig, and rhesus monkey (Wu et al.,
2009). In addition, studies on intestinal
stem cells (Lin et al., 2008), direct conver-
sion of fibroblasts into hepatocytes
(Huang et al., 2011), and demonstration
of Tet3 in germ cell reprogramming (He
et al., 2011) have also received consider-
able attention in the field.
The country’s translational research
efforts meanwhile have focused on stem
cell banking, large animal models, bio-
markers, bioengineering, small mole-
cules, and clinical transplantation, leading
to the filing of numerous patent applica-
tions, many of which have been granted.
In one example of its facility-building
efforts, China boasts the world’s largest
cord blood stem cell bank, based in
Tianjin and co-owned by the country’s
largest hematology institute and hospital
within the Chinese Academy of Medical
Sciences (Peking Medical Union College)
system. Many of these accomplishments
have been made through international
collaborations, in which China-born,
Western-trained stem cell scientists
have played instrumental roles.Cell Stem CellChina has also actively participated
in global stem cell research efforts, such
as the International Stem Cell Forum,
and organized or co-organized a num-
ber of high-profile international con-
ferences on stem cell research (http://
www.selectbiosciences.com/conferences/
IFSC2010/). National and local stem cell
research organizations have also been
active, with at least three independent
national stem cell societies and two major
stem cell industrialization alliances in
existence at present, although the scope
of each varies considerably. A more con-
solidated, better-coordinated approach
would doubtless further enhance the
country’s productivity and opportunities
for exchange, and highlight the best of
China’s stem cell science to the world.
The recently established National Over-
sight and Coordination Committee on
Stem Cell Research, chaired by the
Minister of Science and Technology of
China (Gang Wan), will likely boost
collaborative efforts between stem cell
researchers in China. Further participa-
tion by China’s researchers, especially
those of the younger generation, in inter-
national meetings will also be critical to
achieving these goals.
While trends of stem cell research are
promising, concerns have also been
raised about the scientific quality of
some publications; while recent years
have seen indications of more innovative
contributions, too much of China’s output
remains derivative or incremental. It will
be critical for China to redouble its
efforts to instill in all of its students and
research scientists a sense of the primary
importance of maintaining the highest10, January 6, 2012 ª2012 Elsevier Inc. 13
Table 2. Stem Cell Research Publications, 2006–2010
2006 2007 2008 2009 2010
China 176 277 409 526 677
Japan 519 615 682 672 741
USA 2,422 2,829 3,155 3,482 3,643
World total 6,310 7,537 8,411 9,067 9,608
China (%) 2.79 3.68 4.86 5.80 7.05
Note: All publication counts were obtained from an ISI Thomson Web of Science search on 06/30/
2011. Search terms used therein: CU, country name; TS, stem cell.
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tion to a basic knowledge of biology and
laboratory techniques, students must
uniformly be taught the critical thinking
and standards of research conduct they
will need to make lasting contributions to
the field.
Population Effects
Even granting such concerns, one evident
factor in China’s stem cell research
success is the increasingly high quality
of its research scientists and the facilities
that accommodate them. Thanks to
recent efforts by national and local
governments, universities, and various
ministries and agencies in providing finan-
cial and research incentives, there has
been a surge of well-trained talent return-
ing from abroad, particularly in the stem
cell field. The Ministry of Personnel has
stated that engaging ‘‘internationally
renowned’’ returnees in the science
sector is of primary importance during
its 11th Five Year Plan for 2006–2010,
and MOST also states its aim to ‘‘set
a stage for the outstanding overseas
Chinese people to return home to serve
the country’’ directly in the 973 program.
Heavy investments into infrastructure
have raised many facilities to world-class
levels, and support for education con-
tinues to skyrocket. Funding for research
institutions such as the Chinese Academy
of Science (CAS), the Chinese Academy
of Medical Sciences (CAMS), and the
National Institute of Biological Sciences
(NIBS) has also increased dramatically,
through mechanisms such as the State
Key Laboratories initiative.
A number of metropolitan areas, such
as Beijing, Tianjin, Shanghai, Guangzhou,
Hangzhou, Wuhan, and Chengdu, have
attracted the lion’s share of stem cell
research funding, infrastructure, and
talent, and research synergies can be
clearly seen in these cities. This has14 Cell Stem Cell 10, January 6, 2012 ª2012allowed the establishment of a number
of centers for stem cell research in major
institutions, such as the CAS and CAMS
systems, Peking University, Tsinghua
University, Shanghai Jiao Tong Univer-
sity, Tongji University, Sun Yat-Sen
University, and Zhejiang University, which
have become national powerhouses in
the field. Researchers from smaller cities
or less visible institutes continue to have
less favorable chances at receiving
adequate funding, but this too is changing
as the top universities and institutions
slow recruitment and greater numbers of
highly qualified researchers are recruited
to other top universities in China, such
as the so-called ‘‘985’’ and ‘‘211’’ univer-
sities (which can access special funds
from the Chinese national and local
governments).
China is also churning out myriad
talented graduates who have received
excellent undergraduate education and
high-caliber graduate training, more of
whom are realizing that a stint overseas
is no longer their sole option for top-
quality training. Indeed, some are being
trained in the laboratories of returnee
scientists. Many of these young re-
searchers will doubtless continue their
work at academic and industry work-
places, thus further adding to the produc-
tivity of China’s basic and applied
research. Furthermore, the likelihood of
returning to China for those who choose
to get further training abroad (Ph.D. or
postdoctoral) continues to increase.
However, unlike many other developed
countries, China currently does not have
a sizable workforce of postdoctoral
trainees. This situation may evolve as the
stature of stem cell research rises and
the infrastructure continues to improve.
Transformation in Culture
China’s policymakers must next formu-
late workable strategies for developingElsevier Inc.its burgeoning stem cell enterprise, as
has been achieved in many other areas
over the past 30 years, specifically with
an eye to coordinating the many diverse
initiatives to prevent redundancy and
promote cooperation. While publications
are important for the country to demon-
strate its ability to keep pace with the
cutting edge of the field, they are not the
ultimate goal of its investments. China’s
research force and funding scale are
both only a fraction of that of the United
States or many countries in Europe, and
incremental new findings in basic
research will not win China a leading
position in this arena. What China can
offer uniquely are some of the largest
resources for medical research and inno-
vation in the world. Confronted with the
healthcare needs of a rapidly aging
population of nearly 1.4 billion, the
impetus behind much stem cell research
to date has understandably been clinical
translation and development. The vast
size of its demographic, however, also
represents a remarkable opportunity for
physician-scientists to work with large,
treatment-naive patient populations in
medical conditions that may be underrep-
resented in clinical research in other
countries. With economic modernization,
cancer and heart disease have rapidly
become leading causes of death, and dia-
betes, obesity, and metabolic syndrome
are all on the rise. Traffic and workplace
accidents have left China with more spinal
cord injury patients than any country in the
world, and endemic hepatitis B virus
affects more than 100 million patients
across the country. Thalassemias are
common in southern China, while Keshan
disease, a congestive cardiomyopathy
caused by selenium deficiency, is preva-
lent in the northeast. For this reason,
stem cell research in China should further
emphasize its translational potential to
better meet the needs of patients
suffering a broad spectrum of diseases.
In basic research as well, more emphasis
should be given to the roles and impact of
stem cells in disease, a critical prerequi-
site yet underinvestigated area in stem
cell medicine.
Before China can capitalize on its
growing investments and tremendous
medical opportunities, it will need to
further strengthen its regulatory pathways
to the clinic. China’s regulation of fun-
damental stem cell research provides
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of the first countries in the world to
adopt specific guidelines governing the
production and research use of hESCs,
with joint regulations issued by MOST
and the Ministry of Health (MOH) in
2001, and to ban reproductive cloning in
the following year. This permissive
approach was a boon for Chinese scien-
tists seeking to enter hESC research, as
it provided a clear set of ethical guidelines
for the work in stem cell laboratories.
The regulatory picture for clinical appli-
cation of stem cells, however, remained
muddled for many years, allowing some
hospitals and private clinics to market
various implausible ‘‘stem cell’’ remedies
with little oversight or scientific evidence.
In 2007, MOH published its guidelines,
‘‘Biomedical research ethics review regu-
lations relating to research on human
subjects (clinical trials)’’ in an effort to
standardize government monitoring of
research using human subjects, including
that involving stem cells. And in 2009, the
Ministry promulgated a new law on ad-
vanced medical technologies, requiring
those engaged in highly experimental or
ethically charged medical practices
(such as many stem cell treatments) to
obtain prior MOH approval or face legal
consequences. These measures appear
to have been only partially effective to
date because enforcement is the duty of
regional administrations, and certain
special economic zones and military andarmed police force hospitals operate
with apparent impunity. More effective
policies and uniform enforcement by
a national regulatory agency will be a
key prerequisite for China’s successful
development of translational stem cell
medicine.
China has made an impressive start in
its drive to build a truly world-class stem
cell research enterprise. Now it will need
to exercise sure judgment in sustaining
those efforts that have borne fruit, and
taking a fresh look at those that have
not. All indicators suggest that the country
is on the fast track to reestablishing itself
as one of the world’s foremost producers
of scientific and technological innovation.
This can only be a good thing for the future
of stem cell research and the remarkable
promise it holds.ACKNOWLEDGMENTS
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